| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3978915 | Bulletin du Cancer | 2011 | 10 Pages |
Abstract
Although being active in terms of ORR, bevacizumab plus microtubule targeting agents - mainly taxanes - leads to a high rate of gastro-intestinal perforations and fistula in heavily pre-treated ovarian carcinoma patients.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Irène Asmane, Jean-Emmanuel Kurtz, Agathe Bajard, Jean-Paul Guastalla, Pierre Meeus, Olivier Tredan, Intidhar Labidi Galy, Isabelle Moullet, Philippe Ardisson, Lionel Vincent, David Coeffic, Armelle Dufresne, Jean-Pierre Bergerat, Isabelle Ray-Coquard,